Covalent fragment mapping of KRasG12C revealed novel chemotypes with in vivo potency.

Abstract excerpt

G12C mutant KRas is considered druggable by allele-specific covalent inhibitors due to the nucleophilic character of the oncogenic mutant cysteine at position 12. Discovery of these inhibitors requires the optimization of both covalent and noncovalent interactions. Here, we report covalent fragment screening of our electrophilic fragment library of diverse non-covalent scaffolds equipped with 40 different...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mutation
• Share to Proto-Oncogene Proteins p21(ras)